Literature DB >> 23657264

Prognostic value of perioperative N-terminal pro-B-type natriuretic peptide in noncardiac surgery.

Flávia Kessler Borges1, Mariana Vargas Furtado, Ana Paula Webber Rossini, Carolina Bertoluci, Vinícius Leite Gonzalez, Eduardo Gehling Bertoldi, Denis Maltz Grutcki, Leandro Gazziero Rech, Mariana Magalhães, Carisi Anne Polanczyk.   

Abstract

BACKGROUND: Preoperative NT-proBNP has been shown to predict adverse cardiac outcomes, although recent studies suggested that postoperative NT-proBNP determination could provide additional information in patients submitted to noncardiac surgery.
OBJECTIVE: To evaluate the prognostic value of perioperative NT-proBNP in intermediate and high risk cardiovascular patients undergoing noncardiac surgery.
METHODS: This study prospectively enrolled 145 patients aged ≥ 45 years, with at least one Revised Cardiac Risk Index risk factor and submitted to intermediate or high risk noncardiac surgery. NT-proBNP levels were measured pre- and postoperatively. Short-term cardiac outcome predictors were evaluated by logistic regression models.
RESULTS: During a median follow-up of 29 days, 17 patients (11.7%) experienced major adverse cardiac events (MACE- 14 nonfatal myocardial infarctions, 2 nonfatal cardiac arrests and 3 cardiac deaths). The optimum discriminatory threshold levels for pre- and postoperative NT-proBNP were 917 and 2962 pg/mL, respectively. Pre- and postoperative NT-proBNP (OR 4.7; 95% CI 1.62-13.73; p=0.005 and OR 4.5; 95% CI 1.53-13.16; p=0.006) were significantly associated with MACE. Preoperative NT-proBNP was significantly and independently associated with adverse cardiac events in multivariate regression analysis (adjusted OR 4.2; 95% CI 1.38-12.62; p=0.011).
CONCLUSION: NT-proBNP is a powerful short-term marker of perioperative cardiovascular events in high risk patients. Postoperative levels were less informative than preoperative levels. A single preoperative NT-proBNP measurement should be considered in the preoperative risk assessment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23657264     DOI: 10.5935/abc.20130090

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  5 in total

Review 1.  Sleep apnea in total joint arthroplasty patients and the role for cardiac biomarkers for risk stratification: an exploration of feasibility.

Authors:  M Melanie Lyons; Nitin Y Bhatt; Elizabeth Kneeland-Szanto; Brendan T Keenan; Joanne Pechar; Branden Stearns; Nabil M Elkassabany; Stavros G Memtsoudis; Allan I Pack; Indira Gurubhagavatula
Journal:  Biomark Med       Date:  2016       Impact factor: 2.851

Review 2.  The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.

Authors:  Lisette M Vernooij; Wilton A van Klei; Karel Gm Moons; Toshihiko Takada; Judith van Waes; Johanna Aag Damen
Journal:  Cochrane Database Syst Rev       Date:  2021-12-21

3.  Prediction of perioperative cardiac events through preoperative NT-pro-BNP and cTnI after emergent non-cardiac surgery in elderly patients.

Authors:  Jinling Ma; Qian Xin; Xiujie Wang; Meng Gao; Yutang Wang; Jie Liu
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

4.  Assessment of natriuretic peptides: the heart should be evaluated as a whole.

Authors:  Emre Yalcinkaya; Murat Celik; Galip Buyukturan
Journal:  Arq Bras Cardiol       Date:  2014-03       Impact factor: 2.000

5.  Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients.

Authors:  Sophie L van Veldhuisen; Gijs van Woerden; Martin E W Hemels; Yves G C J America; Rudolf A de Boer; Michiel Rienstra; Dirk J van Veldhuisen; Eric J Hazebroek
Journal:  Surg Obes Relat Dis       Date:  2020-09-02       Impact factor: 4.734

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.